ClinicalTrials.gg
CompletedNCT03117738Updated Aug 10, 2021Results posted

A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease

A Phase 1/2 interventional study of AstroStem and Placebo-Control in Alzheimer Disease, sponsored by Nature Cell Co. Ltd.. Completed at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-08-10.

Sponsored by Nature Cell Co. Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
1,271st of 1,610
21 · median 73
Started
2017
with 68 others
Phase 1/2
67 of 1,941
17 open now
Registered
863rd of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,271st largest by enrollment of the 1,610 interventional ones that give a count, is one of 69 that started in 2017, is one of 67 in phase 1/2, and was the 863rd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects aged 50 and above at the time of signing the form
  • Subjects who can understand and provide written informed consent (assent)
  • Subjects who have diagnosis of probable mild-to-moderate Alzheimer disease according to NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke; Alzheimer's Disease and Related Disorders Association) criteria
  • Subjects who have Score of 16 to 26 at screening
  • Subjects who are taking FDA-approved AD medications (donepezil, galantamine, memantine, rivastigmine or their combinations) treatment on a stable dosage for at least 3 months prior to screening.
  • Subjects who have one (or more) identified adult caregiver who is able to read, understand, and speak the designated language at the study site; either lives with the subject or sees the subject for ≥2 hours/day ≥4 days/week; and agrees to accompany the subject to each study visit
  • Subjects who have a designated study partner who will accompany the subject to all clinic visits and participate in the subject's clinical assessments

Exclusion criteria

Exclusion Criteria:

  • Subjects who are females who are pregnant, nursing, or of while not practicing effective
  • Subjects who have signs of delirium
  • Subjects who have had cortical stroke within the preceding 2 years
  • Subjects who have a prolonged ; >450 msec in male or >470 msec in female at screening
  • Subjects who have diagnosis of severe white matter hyperintensity (WMH), which is defined as ≥ 25mm of the deep white matter and ≥ 10mm of the periventricular capping/banding in lengths
  • Subjects who have diagnosis of dementia or cause of cognitive impairment other than Alzheimer's disease
  • Subjects who have a significant abnormal result in laboratory tests, in the opinion of the investigator
  • Subjects who have participated in any drug, stem cell therapy, or device trial within the previous 3 months at screening
  • Subjects with any current psychiatric diagnosis other than AD if, in the judgment of the investigator, the psychiatric disorder or symptom is likely to confound interpretation of drug effect, affect cognitive assessments, or affect the subject´s ability to complete the study
  • Subjects who are known to have autosomal dominant mutation-associated presenile AD
  • Subjects who show signs of AIDS (Acquired Immunodeficiency Syndrome), (Hepatitis B Virus), (Hepatitis C), VDRL (Venereal Disease Research Laboratory)
  • Subjects who have any conditions that would contraindicate an MRI, such as the presence metallic objects in the eyes, skin, or heart
  • Subjects who have > 4 cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"), a single area of superficial siderosis, or evidence of a prior microhemorrhage as assessed by MRI
  • Subjects who have history of malignant cancer within the last 5 years (The following is a partial list of conditions that are permissible for study entry: non- basal and/or squamous cell carcinoma of the skin, in situ cervical, or non-progressive prostate cancer)
  • Subjects who have suspected active lung disease based on chest X-ray
  • Subjects who are hypersensitive to fetal bovine serum or penicillin
  • Subjects who are currently using , cytotoxic drug, or similar steroidal anti-inflammatory medication (e.g., Prednisone) on a regular basis (exceptions allowed include; regular use of steroidal nasal sprays, topical steroids, and estrogen-replacement therapy)
  • Subjects for whom the investigator judges the liposuction can cause any problems
  • Subjects who have history of local anesthetic allergy
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    AstroStem

    Drug: AstroStem

  • Placebo comparator
    Placebo-Control

    Other: Placebo-Control

Interventions

  • DrugAstroStem

    Autologous adipose tissue derived mesenchymal stem cells (AdMSC)

  • OtherPlacebo-Control

    Saline with 30% auto-serum

06

What researchers measure

Primary outcomes

  1. Treatment Related Adverse Events

    Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results

    Time frame: 30 Weeks

  2. ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)

    Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment

    Time frame: Baseline and 30 Weeks

Secondary outcomes

  1. MMSE (Mini-mental Status Examination)

    Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.

    Time frame: Baseline and 30 Weeks

  2. CDR-SOB (Clinical Dementia Rating-Sum of Boxes)

    Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia

    Time frame: Baseline and 30 Weeks

  3. NPI (Neuropsychiatric Inventory)

    Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.

    Time frame: Baseline and 30 Weeks

  4. GDS (Geriatric Depression Scale)

    Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

    Time frame: Baseline and 30 Weeks

  5. ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)

    Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.

    Time frame: Baseline and 30 Weeks

  6. C-SSRS (Columbia Suicide Severity Rating Scale)

    Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.

    Time frame: Baseline and 30 Weeks

07

Results

Posted Jul 9, 2021

Participant flow

Participant flow — Overall Study
MilestoneAstroStemPlacebo-Control
Started1110
Completed75
Not completed45
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up14

Outcome measures

PrimaryTreatment Related Adverse Events

Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results

Time frame:
30 Weeks
Reported as:
Count of participants · Participants
Treatment Related Adverse Events
ParticipantsAstroStemPlacebo-Control
Treatment Related Adverse Events63
PrimaryADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)

Change of ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale) from Baseline at Week 30 Score range: 0-70 A score of 70 represents the most severe impairment and 0 represents the least impairment

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)
score on a scaleAstroStemPlacebo-Control
ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)5.9 ± 6.83.0 ± 5.4
SecondaryMMSE (Mini-mental Status Examination)

Change of MMSE from baseline at Week 30 Score range: 0-30 A score of 20 to 24 suggests mild dementia, 13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia.

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
MMSE (Mini-mental Status Examination)
score on a scaleAstroStemPlacebo-Control
MMSE (Mini-mental Status Examination)-3.4 ± 2.8-1.4 ± 2.8
SecondaryCDR-SOB (Clinical Dementia Rating-Sum of Boxes)

Changes of CDR-SOB from baseline at Week 30 Score range: 0-18.0 0 = normal, 0.5-4.0 = questionable cognitive dementia, 4.5-9.0 = mild dementia, 9.5-15.5 = moderate dementia, and 16.0-18.0 = severe dementia

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
CDR-SOB (Clinical Dementia Rating-Sum of Boxes)
score on a scaleAstroStemPlacebo-Control
CDR-SOB (Clinical Dementia Rating-Sum of Boxes)1.3 ± 1.70.9 ± 1.5
SecondaryNPI (Neuropsychiatric Inventory)

Changes of NPI from baseline at Week 30 Score range: 0-144 higher score indicates higher disturbance.

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
NPI (Neuropsychiatric Inventory)
score on a scaleAstroStemPlacebo-Control
NPI (Neuropsychiatric Inventory)-1.4 ± 8.5-5.7 ± 11.5
SecondaryGDS (Geriatric Depression Scale)

Changes of GDS from baseline at Week 30 Score range: 0-15 Scores of 0-4 are considered normal, depending on age, education, and complaints; 5-8 indicate mild depression; 9-11 indicate moderate depression; and 12-15 indicate severe depression.

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
GDS (Geriatric Depression Scale)
score on a scaleAstroStemPlacebo-Control
GDS (Geriatric Depression Scale)-0.3 ± 1.30.3 ± 2.1
SecondaryADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)

Change of ADCS-ADL from baseline at Week 30 Score range: 0-78 Lower score indicates greater severity.

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)
score on a scaleAstroStemPlacebo-Control
ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)-4.4 ± 9.0-4.7 ± 9.8
SecondaryC-SSRS (Columbia Suicide Severity Rating Scale)

Changes of C-SSRS from baseline at Week 30 Score range: 0-25 Higher score indicates higher severity.

Time frame:
Baseline and 30 Weeks
Reported as:
Mean · score on a scale
C-SSRS (Columbia Suicide Severity Rating Scale)
score on a scaleAstroStemPlacebo-Control
C-SSRS (Columbia Suicide Severity Rating Scale)-2.1 ± 6.60.0 ± 0.0

Adverse events

Collected over 52 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AstroStem0/11 (0%)3/11 (27.3%)3/11 (27.3%)
Placebo-Control0/10 (0%)1/10 (10%)2/10 (20%)
Most frequent serious events
Most frequent serious events
EventAstroStemPlacebo-Control
Acute Pulmonary OedemaInfections and infestations0/111/10
oesophageal squamous cell carcinoma stage IVNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/110/10
diarrheaGastrointestinal disorders1/110/10
pulmonary embolismRespiratory, thoracic and mediastinal disorders1/110/10
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAstroStemPlacebo-Control
Gastrointestinal Reflux DiseaseGastrointestinal disorders0/111/10
Oedema PeripheralGeneral disorders0/111/10
PainGeneral disorders0/111/10
PyrexiaGeneral disorders0/111/10
DehydrationMetabolism and nutrition disorders1/111/10
HypokalaemiaMetabolism and nutrition disorders0/111/10
AgitationPsychiatric disorders0/111/10
NasopharyngitisInfections and infestations0/111/10
PneumoniaInfections and infestations0/111/10
Open Angle GlaucomaEye disorders1/110/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)AstroStemPlacebo-ControlTotal
Mean72.4 ± 7.675.6 ± 8.273.9 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)AstroStemPlacebo-ControlTotal
Female459
Male7512
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)AstroStemPlacebo-ControlTotal
Hispanic or Latino213
Not-Hispanic or Latino9918
White10919
Black or African American000
Asian112
American Indian or Alaska Native000
Native Hawaiian or Other Pacific Islander000
Other000
Height
Height(cm)AstroStemPlacebo-ControlTotal
Mean167.9 ± 14.4168.3 ± 9.7168.1 ± 12.1
Weight
Weight(kg)AstroStemPlacebo-ControlTotal
Mean74.8 ± 17.264.6 ± 12.069.9 ± 15.5
BMI
BMI(kg/m^2)AstroStemPlacebo-ControlTotal
Mean26.3 ± 4.322.8 ± 3.524.6 ± 4.3
08

Study locations

3 sites
  • ATP Clinical Research
    Costa Mesa, California 92626, United States
  • Syrentis Clinical Research
    Santa Ana, California 92705, United States
  • Valden Medical
    Honolulu, Hawaii 96817, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2017 to primary completion in Jun 2019, 25 months.

Results were first posted in Jul 2021, 2 years after primary completion.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2017
First posted
Apr 18, 2017
StartActual
May 9, 2017
Primary completionActual
Jun 26, 2019
CompletionActual
Aug 31, 2019
Results first posted
Jul 9, 2021
Last update
Aug 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03117738
Lead sponsor
Nature Cell Co. Ltd.
Responsible party
Sponsor
First posted
Apr 18, 2017
Start date
May 9, 2017
Primary completion
Jun 26, 2019
Completion
Aug 31, 2019
Results posted
Jul 9, 2021
Last update
Aug 10, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion